JP2005194283A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005194283A5 JP2005194283A5 JP2005038062A JP2005038062A JP2005194283A5 JP 2005194283 A5 JP2005194283 A5 JP 2005194283A5 JP 2005038062 A JP2005038062 A JP 2005038062A JP 2005038062 A JP2005038062 A JP 2005038062A JP 2005194283 A5 JP2005194283 A5 JP 2005194283A5
- Authority
- JP
- Japan
- Prior art keywords
- fluorine atoms
- substituted
- pharmaceutically acceptable
- solvate
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001153 fluoro group Chemical group F* 0.000 claims 53
- 150000003839 salts Chemical class 0.000 claims 28
- 239000012453 solvate Substances 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 25
- -1 4,4-difluorocyclohexyl Chemical group 0.000 claims 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 16
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims 11
- 239000003085 diluting agent Substances 0.000 claims 10
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 206010006451 bronchitis Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 210000004072 lung Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 238000000634 powder X-ray diffraction Methods 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 3
- LDTVMYHINZSUPV-UHFFFAOYSA-N 5-methyl-3-propan-2-yl-1h-1,2,4-triazole Chemical compound CC(C)C1=NC(C)=NN1 LDTVMYHINZSUPV-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 102000004274 CCR5 Receptors Human genes 0.000 claims 2
- 108010017088 CCR5 Receptors Proteins 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 2
- 206010009137 Chronic sinusitis Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 2
- 206010038997 Retroviral infections Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 101710203526 Integrase Proteins 0.000 claims 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 102000007124 Tachykinin Receptors Human genes 0.000 claims 1
- 108010072901 Tachykinin Receptors Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000002556 chemokine receptor agonist Substances 0.000 claims 1
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 239000002850 integrase inhibitor Substances 0.000 claims 1
- 229940124524 integrase inhibitor Drugs 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 claims 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 230000006490 viral transcription Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0014046.7 | 2000-05-26 | ||
| GB0014046A GB0014046D0 (en) | 2000-05-26 | 2000-05-26 | Compounds useful in therapy |
| GB0015835A GB0015835D0 (en) | 2000-06-27 | 2000-06-27 | Compounds useful in therapy |
| GB0015835.2 | 2000-06-27 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001586293A Division JP3693957B2 (ja) | 2000-05-26 | 2001-05-09 | 療法において有用なトロパン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005194283A JP2005194283A (ja) | 2005-07-21 |
| JP2005194283A5 true JP2005194283A5 (enExample) | 2008-06-19 |
| JP4854970B2 JP4854970B2 (ja) | 2012-01-18 |
Family
ID=26244452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001586293A Expired - Lifetime JP3693957B2 (ja) | 2000-05-26 | 2001-05-09 | 療法において有用なトロパン誘導体 |
| JP2005038062A Expired - Lifetime JP4854970B2 (ja) | 2000-05-26 | 2005-02-15 | 療法において有用なトロパン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001586293A Expired - Lifetime JP3693957B2 (ja) | 2000-05-26 | 2001-05-09 | 療法において有用なトロパン誘導体 |
Country Status (50)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3693957B2 (ja) * | 2000-05-26 | 2005-09-14 | ファイザー・インク | 療法において有用なトロパン誘導体 |
| WO2002100848A1 (en) * | 2001-06-12 | 2002-12-19 | Sk Corporation | Novel phenylalkyl diamine and amide analogs |
| SE0103818D0 (sv) | 2001-11-15 | 2001-11-15 | Astrazeneca Ab | Chemical compounds |
| SE0200919D0 (sv) * | 2002-03-25 | 2002-03-25 | Astrazeneca Ab | Chemical compounds |
| GB0208071D0 (en) * | 2002-04-08 | 2002-05-22 | Pfizer Ltd | Tropane derivatives useful in therapy |
| EA007590B1 (ru) * | 2002-04-08 | 2006-12-29 | Пфайзер Инк. | Производные тропана в качестве модуляторов ccr5 |
| US6855724B2 (en) | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| MXPA04011577A (es) * | 2002-05-23 | 2005-03-07 | Pfizer | Metodo para la identificacion de un ligando, por el cual se mide el tiempo de residencia del receptor. |
| DE60323133D1 (de) | 2002-12-13 | 2008-10-02 | Smithkline Beecham Corp | Cyclohexylverbindungen als ccr5-antagonisten |
| SE0301369D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Chemical compounds |
| DE10336274A1 (de) * | 2003-08-07 | 2005-03-10 | Honeywell Specialty Chemicals | Verfahren zur Herstellung von geminalen Difluoralkanen |
| CA2537185A1 (en) | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
| CA2579609A1 (en) | 2003-09-10 | 2005-03-17 | Virochem Pharma Inc. | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity |
| ES2295924T3 (es) * | 2003-10-03 | 2008-04-16 | Pfizer, Inc. | Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion. |
| TW200610761A (en) | 2004-04-23 | 2006-04-01 | Astrazeneca Ab | Chemical compounds |
| BRPI0511982A (pt) | 2004-06-09 | 2008-01-22 | Hoffmann La Roche | compostos antiviróticos heterocìclicos |
| US20060122220A1 (en) * | 2004-11-19 | 2006-06-08 | Boehringer Ingelheim International Gmbh | Method for treating HIV infection through co-administration of tipranavir and UK-427,857 |
| WO2006064340A2 (en) * | 2004-12-13 | 2006-06-22 | Pfizer Limited | Process for the preparation of n-acyl beta-aminoaldehydes |
| US7665658B2 (en) | 2005-06-07 | 2010-02-23 | First Data Corporation | Dynamic aggregation of payment transactions |
| KR20080035653A (ko) | 2005-07-22 | 2008-04-23 | 프로제닉스 파머슈티컬스, 인코포레이티드 | Ｈｉｖ―１ 감염 환자에서 바이러스 부하를 감소시키는방법 |
| JP2009515826A (ja) | 2005-10-19 | 2009-04-16 | エフ．ホフマン−ラ ロシュ アーゲー | フェニル−アセトアミドｎｎｒｔ阻害剤 |
| EP2043640A2 (en) * | 2006-06-12 | 2009-04-08 | Pfizer Products Inc. | Ccr5 antagonist for enhancing immune reconstitution and treating opportunistic infection in hiv patients |
| AU2007286345B2 (en) | 2006-08-16 | 2012-03-08 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| US7932235B2 (en) | 2006-11-17 | 2011-04-26 | Concert Pharmaceuticals, Inc. | Triazolyl tropane derivatives |
| JP5415957B2 (ja) | 2006-12-13 | 2014-02-12 | エフ．ホフマン−ラ ロシュ アーゲー | 非ヌクレオシド逆転写酵素阻害剤としての２−（ピペリジン−４−イル）−４−フェノキシ−又はフェニルアミノ−ピリミジン誘導体 |
| EP2121676A1 (en) * | 2006-12-19 | 2009-11-25 | Auspex Pharmaceuticals, Inc. | Preperation and utility of ccr5 inhibitors |
| US20080207659A1 (en) | 2007-02-15 | 2008-08-28 | Asit Kumar Chakraborti | Inhibitors of phosphodiesterase type 4 |
| WO2008132128A2 (en) * | 2007-04-27 | 2008-11-06 | Solvay (Société Anonyme) | Synthesis of a pharmaceutically active compound |
| RU2368613C1 (ru) * | 2008-02-19 | 2009-09-27 | Институт молекулярной генетики Российской Академии наук (ИМГ РАН) (Статус Государственного учреждения) | Равномерно меченный тритием 4,4-дифтор-n-{(1s)-3-[3-(3-изопропил-5-метил-4н-1,2,4-триазол-4-ил)-8-азабицикло[3.2.1]окт-8-ил]-1-фенилпропил}циклогексан карбодиимид |
| WO2009111218A2 (en) * | 2008-02-29 | 2009-09-11 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
| CN101712679B (zh) * | 2008-10-08 | 2013-04-10 | 中国科学院上海药物研究所 | 一种酰胺类化合物、其药物组合物及其制备方法和用途 |
| US8592395B2 (en) * | 2009-07-24 | 2013-11-26 | Glaxosmithkline Llc | Therapeutic compounds |
| CN102140104B (zh) * | 2010-02-03 | 2014-11-12 | 中国科学院上海药物研究所 | 1-(3-(s)-氨基丙基)-哌啶-4-氨基酰胺类化合物、其药物组合物及其制备方法和用途 |
| BR112012024522A2 (pt) | 2010-04-02 | 2017-08-08 | Phivco 1 Llc | combinação, uso de uma combinação, composição farmacêutica, forma de dosagem única , kit, e, método para tratar um distúrbio |
| CN103159754A (zh) * | 2011-12-19 | 2013-06-19 | 中国科学院上海药物研究所 | 一种氨基丙基取代托烷胺类化合物、其药物组合物及其制备方法和用途 |
| JP2015536940A (ja) | 2012-10-29 | 2015-12-24 | シプラ・リミテッド | 抗ウイルス性ホスホネート類似体及びその製造方法 |
| CZ306455B6 (cs) | 2013-04-26 | 2017-02-01 | Zentiva, K.S. | Nový způsob syntézy Maravirocu |
| CN103497164B (zh) * | 2013-09-23 | 2015-12-23 | 西安近代化学研究所 | 一种蒽衍生物及其制备方法 |
| CN104304248B (zh) * | 2014-10-23 | 2016-08-10 | 西北农林科技大学 | 3-芳基丙酸酯类化合物作为制备杀螨药物的应用 |
| CN104402883B (zh) * | 2014-10-24 | 2016-04-27 | 艾琪康医药科技（上海）有限公司 | 4，4-二氟金刚烷甲酰胺衍生物、药物组合物及其制备方法和用途 |
| CN104387379B (zh) * | 2014-11-26 | 2017-01-11 | 扬州氟药科技有限公司 | 一种二氟亚甲基哌啶甲酰胺衍生物及其制备方法和用途 |
| CN104860946A (zh) * | 2015-05-14 | 2015-08-26 | 湖北生物医药产业技术研究院有限公司 | Ccr5拮抗剂的制备方法 |
| CN107879963A (zh) * | 2016-09-29 | 2018-04-06 | 中国科学院上海药物研究所 | 新型手性配体、金属螯合物、多种非天然氨基酸、马拉维诺及其关键中间体的合成方法 |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5648511A (en) * | 1990-11-19 | 1997-07-15 | G.D. Searle & Co. | Method for making intermediates useful in the synthesis of retroviral protease inhibitors |
| FR2676444B1 (fr) * | 1991-05-16 | 1995-03-10 | Sanofi Elf | Nouveaux derives d'amino-3 pyridazines actifs sur le systeme nerveux central, procede de preparation et compositions pharmaceutiques en contenant. |
| GB9310713D0 (en) * | 1993-05-24 | 1993-07-07 | Zeneca Ltd | Aryl substituted heterocycles |
| PL183025B1 (pl) * | 1994-04-19 | 2002-05-31 | Neurosearch As | Pochodne tropanu, sposób ich otrzymywania i zawierające je kompozycje |
| GB9523526D0 (en) * | 1995-11-17 | 1996-01-17 | Zeneca Ltd | Therapeutic compounds |
| DE19546462A1 (de) * | 1995-12-13 | 1997-06-19 | Bayer Ag | Diarylacetylenketone |
| AU1208397A (en) * | 1995-12-28 | 1997-07-28 | Takeda Chemical Industries Ltd. | Diphenylmethane derivatives as mip-1alpha/rantes receptor antagonists |
| US6323206B1 (en) * | 1996-07-12 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| JP2000516210A (ja) * | 1996-07-12 | 2000-12-05 | ロイコサイト，インコーポレーテッド | ケモカインレセプターアンタゴニストとその使用方法 |
| WO1998025604A1 (en) * | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Spiro-substituted azacycles as modulators of chemokine receptor activity |
| WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU8576098A (en) * | 1997-07-25 | 1999-02-16 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| EP1047675A1 (en) * | 1998-01-21 | 2000-11-02 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
| US7217714B1 (en) * | 1998-12-23 | 2007-05-15 | Agouron Pharmaceuticals, Inc. | CCR5 modulators |
| EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| JP3693957B2 (ja) * | 2000-05-26 | 2005-09-14 | ファイザー・インク | 療法において有用なトロパン誘導体 |
-
2001
- 2001-05-09 JP JP2001586293A patent/JP3693957B2/ja not_active Expired - Lifetime
- 2001-05-09 SK SK1643-2002A patent/SK286129B6/sk active Protection Beyond IP Right Term
- 2001-05-09 DK DK04004193T patent/DK1526134T3/da active
- 2001-05-09 OA OA1200200343A patent/OA12264A/en unknown
- 2001-05-09 PT PT04004193T patent/PT1526134E/pt unknown
- 2001-05-09 DK DK01925808T patent/DK1284974T3/da active
- 2001-05-09 DE DE200812000011 patent/DE122008000011I1/de active Pending
- 2001-05-09 CZ CZ20023806A patent/CZ299102B6/cs not_active IP Right Cessation
- 2001-05-09 MX MXPA02011631A patent/MXPA02011631A/es active IP Right Grant
- 2001-05-09 AU AU5248201A patent/AU5248201A/xx active Pending
- 2001-05-09 PL PL359267A patent/PL200551B1/pl unknown
- 2001-05-09 CN CNB018088287A patent/CN1279040C/zh not_active Expired - Lifetime
- 2001-05-09 EP EP20080163025 patent/EP1990341B1/en not_active Expired - Lifetime
- 2001-05-09 ME MEP-2008-693A patent/ME00555B/me unknown
- 2001-05-09 NZ NZ521477A patent/NZ521477A/en not_active IP Right Cessation
- 2001-05-09 AT AT04004193T patent/ATE407134T1/de active
- 2001-05-09 ES ES04004193T patent/ES2311126T3/es not_active Expired - Lifetime
- 2001-05-09 EP EP20040004193 patent/EP1526134B1/en not_active Expired - Lifetime
- 2001-05-09 HR HR20020938A patent/HRP20020938B1/xx not_active IP Right Cessation
- 2001-05-09 AP APAP/P/2002/002663A patent/AP1965A/en active
- 2001-05-09 EE EEP200200656A patent/EE05110B1/xx active Protection Beyond IP Right Term
- 2001-05-09 RS YUP82202 patent/RS50904B/sr unknown
- 2001-05-09 EP EP20010925808 patent/EP1284974B1/en not_active Expired - Lifetime
- 2001-05-09 BR BRPI0110955A patent/BRPI0110955B8/pt not_active IP Right Cessation
- 2001-05-09 TR TR200400541T patent/TR200400541T4/xx unknown
- 2001-05-09 IL IL15253101A patent/IL152531A0/xx unknown
- 2001-05-09 RS RSP-2009/0438A patent/RS51436B/sr unknown
- 2001-05-09 DE DE60135685T patent/DE60135685D1/de not_active Expired - Lifetime
- 2001-05-09 SI SI200130862T patent/SI1526134T1/sl unknown
- 2001-05-09 HU HU0302474A patent/HU225810B1/hu active Protection Beyond IP Right Term
- 2001-05-09 EA EA200401056A patent/EA007580B1/ru not_active IP Right Cessation
- 2001-05-09 CN CNB2005100068151A patent/CN100355753C/zh not_active Expired - Lifetime
- 2001-05-09 AT AT01925808T patent/ATE260914T1/de active
- 2001-05-09 EA EA200201141A patent/EA005382B1/ru not_active IP Right Cessation
- 2001-05-09 AU AU2001252482A patent/AU2001252482B2/en not_active Expired
- 2001-05-09 CA CA 2408909 patent/CA2408909C/en not_active Expired - Lifetime
- 2001-05-09 PT PT01925808T patent/PT1284974E/pt unknown
- 2001-05-09 DE DE2001602233 patent/DE60102233T2/de not_active Expired - Lifetime
- 2001-05-09 DZ DZ013464A patent/DZ3464A1/fr active
- 2001-05-09 GE GEAP2001004960 patent/GEP20063799B/en unknown
- 2001-05-09 ES ES01925808T patent/ES2215129T3/es not_active Expired - Lifetime
- 2001-05-09 SI SI200130090T patent/SI1284974T1/xx unknown
- 2001-05-09 KR KR10-2002-7015934A patent/KR100523501B1/ko not_active Expired - Lifetime
- 2001-05-09 KR KR1020057003492A patent/KR100548854B1/ko not_active Expired - Lifetime
- 2001-05-09 WO PCT/IB2001/000806 patent/WO2001090106A2/en not_active Ceased
- 2001-05-09 ES ES08163025T patent/ES2401812T3/es not_active Expired - Lifetime
- 2001-05-21 TW TW90112055A patent/TWI230160B/zh not_active IP Right Cessation
- 2001-05-22 EG EG20010535A patent/EG24137A/xx active
- 2001-05-22 PA PA8517101A patent/PA8517101A1/es unknown
- 2001-05-23 MY MYPI20094132A patent/MY156920A/en unknown
- 2001-05-23 MY MYPI20012461 patent/MY131019A/en unknown
- 2001-05-23 MY MYPI20041980 patent/MY153023A/en unknown
- 2001-05-24 AR ARP010102486 patent/AR028622A1/es active IP Right Grant
- 2001-05-24 UY UY26727A patent/UY26727A1/es not_active IP Right Cessation
- 2001-05-24 PE PE2001000476A patent/PE20011371A1/es active IP Right Grant
- 2001-05-25 TN TNSN01077 patent/TNSN01077A1/fr unknown
-
2002
- 2002-09-23 BG BG107140A patent/BG65966B1/bg unknown
- 2002-09-24 IS IS6565A patent/IS2511B/is unknown
- 2002-10-28 IL IL152531A patent/IL152531A/en active Protection Beyond IP Right Term
- 2002-10-28 CU CU20020243A patent/CU23288B7/es unknown
- 2002-10-31 NO NO20025227A patent/NO327892B1/no not_active IP Right Cessation
- 2002-11-14 MA MA26910A patent/MA26902A1/fr unknown
-
2005
- 2005-02-15 JP JP2005038062A patent/JP4854970B2/ja not_active Expired - Lifetime
-
2007
- 2007-03-27 AR ARP070101273 patent/AR060159A2/es unknown
-
2008
- 2008-02-22 NL NL300338C patent/NL300338I2/nl unknown
- 2008-02-22 LU LU91417C patent/LU91417I2/fr unknown
- 2008-02-25 LT LTPA2008004C patent/LTC1284974I2/lt unknown
- 2008-03-04 FR FR08C0007C patent/FR08C0007I2/fr active Active
- 2008-03-17 CY CY200800006C patent/CY2008006I1/el unknown
- 2008-07-16 CR CR10145A patent/CR10145A/es unknown
- 2008-10-24 CY CY081101203T patent/CY1108451T1/el unknown
-
2010
- 2010-04-08 NO NO2010007C patent/NO2010007I2/no unknown
-
2020
- 2020-06-30 NO NO2020019C patent/NO2020019I1/no not_active IP Right Cessation
-
2022
- 2022-04-19 CY CY2022009C patent/CY2022009I1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005194283A5 (enExample) | ||
| JP7083398B2 (ja) | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 | |
| JP2020183410A5 (enExample) | ||
| JP2021191798A (ja) | Ｈｉｖカプシド阻害剤の固体形態 | |
| RU2420284C2 (ru) | Антагонист ccr5 для усиления иммуновосстановительной терапии и лечения оппортунистической инфекции у пациентов с вич | |
| JP2021178873A (ja) | Ｈｉｖカプシド阻害剤のコリン塩形態 | |
| JP4874107B2 (ja) | Ｈｉｖ及び炎症の治療のためのｃｃｒ５受容体拮抗活性を有するイミダゾピリジン置換トロパン誘導体 | |
| CN109890808A (zh) | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 | |
| TW200815423A (en) | Hetero compound | |
| JP2818299B2 (ja) | ウイルス感染の治療におけるジデオキシヌクレオシドアナローグの使用 | |
| JP2005509038A5 (enExample) | ||
| US10004740B2 (en) | Prodrugs of HIV reverse transcriptase inhibitors | |
| JP2017528506A5 (enExample) | ||
| JP2008540672A (ja) | 病状に起因する性的機能不全の治療方法 | |
| JP5465233B2 (ja) | 置換ピラゾールアミドおよびその使用 | |
| JP2018529714A (ja) | Ｈｉｖの処置のための化合物および組合せ物 | |
| US12138256B2 (en) | Treatment of cardiopulmonary disorders | |
| AU702618B2 (en) | 4-(2-amino-6-(cyclopropylamino)-9H-purin-9-yl)-2 -cyclopentene-1-methanol succinate as antiviral agent | |
| KR20240136361A (ko) | 약학적 건조 분말 흡입 제제 | |
| JP6781848B2 (ja) | 新規なピロロピリジン誘導体、その製造方法及び用途 | |
| JP2010534670A5 (enExample) | ||
| TW201412720A (zh) | 三（雜）芳基吡唑及其應用 | |
| JP2007269628A (ja) | 医薬化合物の結晶 | |
| JP2008525418A (ja) | ケモカインｃｃｒ５受容体に対して活性を有する８−アザ−ビシクロ（３．２．１）オクタン誘導体 | |
| AU2014270596A1 (en) | Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception |